<DOC>
	<DOCNO>NCT01379196</DOCNO>
	<brief_summary>The purpose study examine effect Azithromycin ( macrolide class antibiotic ) , give three time weekly , patient active moderate-severe , non sight-threatening , Graves Orbitopathy . Indices follow-up include : - Clinical activity score - Anti-TSH receptor antibody level - Thickening extraocular muscle per ultrasound - Quality life score Graves Orbitopathy patient</brief_summary>
	<brief_title>Use Azithromycin Immunomodulatory Therapy Grave 's Orbitopathy</brief_title>
	<detailed_description>Graves Orbitopathy ( GO ) autoimmune inflammatory disorder cause visual morbidity , cosmetic morbidity interference quality life . The disease inflammatory stage non-inflammatory , fibrotic stage . Treatment inflammatory stage moderate-severe GO include steroid , recommend EUGOGO consortium . However , length treatment need risk steroid side-effects may lead multiple undesired treatment induced morbidity . Antibiotics macrolide group posses know immune-modulatory effect separate antibacterial mode action . This mode action lead routine use macrolide antibiotic delay graft rejection follow lung transplant . We propose test effect class antibiotic non-sight threatening , moderate-severe , inflammatory GO .</detailed_description>
	<mesh_term>Eye Diseases</mesh_term>
	<mesh_term>Graves Ophthalmopathy</mesh_term>
	<criteria>Clinical diagnosis Graves Orbitopathy Clinical activity score high 2 Must able swallow tablet sightthreatening Graves Orbitopathy Diplopia primary gaze Macrolide allergy intolerance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Graves Orbitopathy</keyword>
	<keyword>Macrolide antibiotic</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Clinical Activity Score</keyword>
</DOC>